Compare Incyte Corporation (INCY) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SMX Security Matters plc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while SMX Security Matters plc trades at $16.48 (market cap $17.04M). The key difference: Incyte Corporation is far larger — about 1440.1× SMX Security Matters plc's market cap, and Incyte Corporation is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| INCY | SMX | |
|---|---|---|
Market Cap | $24.54B | $17.04M |
Sector | Health | Technology |
52-Week High | $129.93 | $103.71K |
52-Week Low | $81.61 | $12.87 |
Enterprise Value | $20.04B | -$14.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
SMX (Security Matters) trades at $16.16, up 2.28% on the day, but technical indicators signal a bearish trend with the stock near its pivot point. The company reported a net loss of $169.18M for 2025, with negative profitability metrics (ROE -819.22%), though recent news highlights a strengthened balance sheet and progress in commercializing its materials traceability platform amid growing regulatory demand for recycled plastics.
The outlook remains high-risk given persistent losses and cash burn, offset by potential from regulatory tailwinds in recycling. Investors face significant execution risk, but the company's niche in material verification could capture value if commercialization accelerates. The stock's viability hinges on reversing operational losses and achieving sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
